The decision was expected, because the FDA had repeatedly restricted the drug’s use in the Northeast and other regions as the BA.2 version of omicron became dominant.
from Section Page News - Modern Healthcare https://ift.tt/SL9AUzf
Tuesday, April 5, 2022
US pulls GSK's COVID drug as omicron sibling dominates casesUS pulls GSK's COVID drug as omicron sibling dominates casesUS pulls GSK's COVID drug as omicron sibling dominates cases
US pulls GSK's COVID drug as omicron sibling dominates cases
from Section Page News - Modern Healthcare https://ift.tt/SL9AUzf
from Section Page News - Modern Healthcare https://ift.tt/SL9AUzf
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment